GlobeNewswire Inc.··Alethio TherapeuticsAlethio Therapeutics Unveils First Mutation-Agnostic Antibody for $2B Essential Thrombocythemia Market
Alethio Therapeutics unveils ATX-011, a first-in-class antibody for treating Essential Thrombocythemia, with IND submission targeted for Q1 2027 and clinical data expected H1 2028.
AZNmonoclonal antibodyclinical development